Background High plasma HDL cholesterol is associated with reduced risk of myocardial infarction, but whether this association is causal is unclear. Exploiting the fact that genotypes are randomly assigned at meiosis, are independent of non-genetic confounding, and are unmodifi ed by disease processes, mendelian random isation can be used to test the hypothesis that the association of a plasma biomarker with disease is causal.
Introduction
Cholesterol fractions such as LDL and HDL cholesterol are among the most commonly measured biomarkers in clinical medicine. 1 Observational studies have shown that LDL and HDL cholesterol have opposing associations with risk of myocardial infarction, with LDL cholesterol being positively associated and HDL cholesterol being inversely associated. 2, 3 However, observational studies cannot distinguish between a causal role in the pathological process and a marker of the underlying patho physiology. These two possibilities can be distinguished in human beings by changes of the cholesterol fractions in large-scale randomised trials or by studies of inherited DNA variation. For LDL cholesterol, the results of both randomised trials of LDL-cholesterol-lowering treatments 4 and from human mendelian diseases 5, 6 are concordant and suggest that plasma LDL cholesterol is causally related to risk of myocardial infarction. However, the available evidence for the causal relevance of HDL cholesterol from randomised trials or mendelian diseases is scarce and inconsistent. 7, 8 If a particular plasma biomarker is directly involved in an underlying pathological process, then inherited variation changing plasma concentrations of this biomarker should aff ect risk of disease in the direction and magnitude predicted by the plasma concentrations. Referred to as mendelian randomisation, [9] [10] [11] this analytical approach has been previously applied to plasma HDL cholesterol, albeit with restricted sample sizes, a small number of single nucleotide polymorphisms (SNPs) at a few genes, and with SNPs that aff ect multiple lipid fractions. 8, [12] [13] [14] [15] Hence, these studies have not been able to resolve fully the possible causal relevance of HDL cholesterol concentrations for risk of myocardial infarction.
Recently, we have used the genome-wide association approach to identify SNPs that aff ect blood lipid concentrations. 16, 17 Additionally, through resequencing, we identifi ed a loss-of-function coding SNP at the endothelial lipase gene (LIPG Asn396Ser) that aff ects plasma HDL cholesterol in isolation. 18, 19 Here, we use these SNPs in case-control studies and prospective cohort studies to test the hypothesis that genetically raised plasma HDL cholesterol might be protective for myocardial infarction.
Methods

Study design
The study design consisted of two components. First, using a case-control design, we tested lipid-associated SNPs individually for association with risk of myocardial infarction. Second, using a mendelian randomisation design, we tested two instruments: (1) a single SNP that related exclusively to plasma HDL cholesterol (a loss-offunction coding polymorphism at the endothelial lipase gene, LIPG Asn396Ser, rs61755018); and (2) a genetic score consisting of 14 common SNPs that exclusively associate with HDL cholesterol.
Study participants
Characteristics of cases of myocardial infarction and controls are shown in appendix p 19. Data for up to 19 139 cases of myocardial infarction and 50 812 myocardial-infarction-free controls were available from 30 studies. Characteristics of the participants in six prospective cohort studies are shown in the appendix p 20. 50 763 participants from six cohort studies were studied and, of these, 4228 developed an incident fatal or non-fatal myocardial infarction. All participants were of self-reported European or South Asian ancestry.
Statistical analysis
In myocardial infarction cases and controls, we tested each of 25 SNPs for association with myocardial infarction in up to 30 studies. These 25 SNPs represented the initial polymorphisms mapped for plasma HDL or LDL cholesterol concentrations with a genomewide association approach. 16 Each selected SNP has been associated with either HDL or LDL cholesterol at p<5×10 -⁸. Genotyping details are provided in the appendix p 2. We undertook logistic regression with the outcome variable of myocardial infarction status, predictor variable of individual SNP genotype, and covariates of age, sex, and principal components of ancestry. We assumed a log-additive genetic model. Overall association for each SNP was evaluated with a fi xed-eff ects inverse-varianceweighted meta-analysis.
Fatal or non-fatal myocardial infarction outcomes were ascertained in each of six prospective cohort studies as described in the appendix p 10. We constructed logistic regression models to examine the association of LIPG Asn396Ser genotype with myocardial infarction status, excluding participants who had had a previous myocardial infarc tion or ischaemic stroke. The predictor variable of LIPG Asn396Ser genotype was modelled in an additive model (ie, 0, 1, 2 copies of the 396Ser allele). Covariates in the model included age and sex. Overall association for each SNP was evaluated across the six studies with fi xedeff ects inverse-variance-weighted meta-analysis.
We estimated a predicted risk for LIPG Asn396Ser on the basis of the association of this SNP with plasma HDL cholesterol (appendix p 21) and the association of plasma HDL cholesterol with myocardial infarction (appendix p 22) in the population. Details are provided in the appendix p 2.
We undertook instrumental variable analysis using LIPG Asn396Ser in six prospective cohort studies as listed in the appendix p 23. We additionally did an instrumental variable analysis using multiple genetic variants as instruments. 20 Details of the instrumental variable analysis methods are provided in the appendix p 4. We regarded a two-tailed p<0·05 as nominally signifi cant. Heterogeneity statistics were calculated as described.
21 SAS version 9.1, the R package, STATA, or PLINK software were used for all statistical analyses.
22
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Results
To validate the statistical framework and clinical samples, we fi rst tested SNPs related to plasma LDL cholesterol in 
*Data presented from a meta-analysis of seven cohorts (n up to 19 840) as presented in reference 16; the eff ect of each SNP on a lipid trait was modelled if the association of the SNP with a plasma lipid trait exceeded nominal signifi cance (p<0·05). †Loci and SNPs that exceeded nominal signifi cance (p<0·05) for association of modelled allele with MI; all modelled alleles increased LDL cholesterol. ‡The C allele at this LPA variant is related to increased plasma lipoprotein(a) as presented in reference 16. ; table 2 ). Of note, at the HNF4A locus, the HDLcholesterol-raising allele was surprisingly associated with increased risk of myocardial infarction (p=0·0009). All six SNPs associated with both HDL cholesterol and myocardial infarction had additional eff ects on plasma LDL cholesterol or triglycerides, or both (p<5×10 -⁸ for the additional eff ects on LDL cholesterol or triglycer ides). For example, at APOA1-APOC3-APOA4-APOA5 rs6589566, the allele associated with increased HDL cholesterol also relates to reduced LDL cholesterol and reduced triglycerides. The pleiotropic eff ects of such SNPs undermine the ability to defi ne a causal role for HDL cholesterol, independent of eff ects on LDL cholesterol or triglycerides.
To evaluate plasma HDL cholesterol specifi cally, we undertook mendelian randomisation, a form of instrumental variable analysis. 23 We identifi ed a variant that aff ected only plasma HDL cholesterol without changing other lipid or non-lipid cardiovascular risk factors. In the LIPG gene, roughly 2·6% of individuals carry a serine substitution at aminoacid 396 (substituted for wild-type asparagine). Carrier status for 396Ser was associated with signifi cant increases in HDL cholesterol in each of four prospective cohort studies, with the eff ect size ranging from 0·08 mmol/L to 0·28 mmol/L per copy of the Ser allele (fi gure 1, appendix p 21; p=0·002 in FHS, p=0·02 in CCHS, p=5×10 -⁶ in MDC, and p=7×10 -⁷ in ARIC).
In a meta-analysis including all four studies, carrier status for 396Ser was associated with an increase of roughly 0·29 SD units in HDL cholesterol (p=8×10 -¹³). There was no evidence of heterogeneity across the four studies (I²=0·58; Cochran's heterogeneity p=0·07). LIPG Asn396Ser was not signifi cantly associated with other risk factors for myocardial infarction including plasma LDL cholesterol, triglycerides, systolic blood pressure, body-mass index, risk of type 2 diabetes, fasting glucose, plasma C-reactive protein, waist-to-hip ratio, fi brinogen, and small LDL particle concentration (p>0·05 for each; appendix pp [24] [25] [26] . Therefore, LIPG Asn396Ser satisfi ed the three main criteria for mendelian randomisation analysis-ie, that the genotype should be associated with an intermediate biomarker (fi gure 1), should not be associated with confounding factors (appendix pp 24-46), and should exert its eff ect on the clinical outcome only through the specifi c intermediate biomarker (appendix p 22) . 24 Under the model that plasma HDL cholesterol causally relates to risk of myocardial infarction, individuals with an inherited increase in HDL cholesterol (eg, those carrying the LIPG 396Ser allele) are expected to have reduced risk of myocardial infarction. On the basis of the associations between SNPs and HDL cholesterol, and HDL cholesterol and myocardial infarction, we estimated that carriage of LIPG 396Ser should decrease risk of myocardial infarction by 13% (odds ratio [OR] 0·87, 95% CI 0·84-0·91).
To establish whether LIPG 396Ser carriers are indeed protected from risk of myocardial infarction, we studied the association of LIPG Asn396Ser with incident myocardial infarction in 50 763 participants from six prospective cohort studies, the gold standard with respect to epidemiological study design. Of these participants, 4228 developed a fi rst myocardial infarction event. LIPG Asn396Ser was not associated with myocardial infarction in any of the six studies (fi gure 2). Combining these studies in a meta-analysis, LIPG Asn396Ser allele was not associated with myocardial infarction (OR 1·10, 95% CI 0·89-1·37, p=0·37; fi gure 2). There was no evidence for heterogeneity across the six cohorts (I²=0·17; Cochran's heterogeneity p=0·31). We also studied LIPG Asn396Ser in case-control studies involving an additional 16 685 cases of myocardial infarction and 48 872 controls and noted that this SNP was not associated with myocardial infarction (OR 0·94, 95% CI 0·82-1·09, p=0·41; table 2, fi gure 2), with no evidence of heterogeneity across the 14 case-control studies (I²=0·34; Cochran's heterogeneity p=0·11). Finally, we used meta-analysis to combine the evidence from both the prospective studies and case-control studies (116 320 participants; 20 913 cases and 95 407 controls). In all available samples, LIPG Asn396Ser remained not associated with risk of myocardial infarction (OR 0·99, 95% CI 0·88-1·11, p=0·85; fi gure 2). There was no evidence for heterogeneity across all 20 studies (I²=0·30; Cochran's heterogeneity p=0·10).
We formally estimated the magnitude of an association of genetically raised HDL cholesterol with myocardial infarction, using LIPG Asn396Ser as the instrument. The mendelian randomisation estimate was computed from the ratio of the coeffi cient of the association between genotype and disease to that of the association between genotype and plasma HDL cholesterol; this instrumental variable estimate refl ects the potential causal eff ect of plasma HDL cholesterol on the risk of myocardial infarction. Table 3 presents the instrumental variable estimate for the association of plasma HDL cholesterol with risk of myocardial infarction in each of six prospective cohort studies. In each study, genetically raised plasma HDL cholesterol was not associated with risk of myocardial infarction. In meta-analysis, genetically raised plasma HDL cholesterol was also not associated with risk of myocardial infarction (OR 1·02 per 0·03 mmol/L [1 mg/dL] increase in HDL cholesterol, 95% CI 0·95-1·09, p=0·64; OR 1·28 per 0·39 mmol/L [15 mg/dL] increase in HDL cholesterol, 95% CI 0·46-3·61, p=0·64).
Statistical power for instrumental variable analysis could be increased if multiple genetic variants in combination are used as instruments, according to a recent proposal. 20 From our genome-wide association study of plasma lipid traits involving more than 100 000 individuals, 17 we noted that 13 common SNPs had statistical evidence at genome-wide levels of signifi cance (p<5×10 -⁸) for plasma LDL cholesterol and no evidence for association with triglycerides (p>0·01) or HDL cholesterol (p>0·01). We constructed a genetic score for LDL cholesterol combining the LDLcholesterol-raising alleles at each of these 13 SNPs (appendix p 27). 25 We also noted that 14 common SNPs had statistical evidence at genome-wide levels of signifi cance (p<5×10 -⁸) for plasma HDL cholesterol and no evidence for association with triglycerides (p>0·01) or LDL cholesterol (p>0·01). We constructed a genetic score for HDL cholesterol combining the HDLcholesterol-raising alleles at each of these 14 SNPs (appendix p 28). Each SNP was given a weight based on the degree of change in LDL or HDL cholesterol as estimated in roughly 100 000 individuals. 17 We tested the association of genetic scores for LDL and HDL cholesterol separately for association with myocardial infarction in up to 53 146 cases and controls from the CARDIoGRAM study. 26 From observational epidemiology, an increase of 1 SD in usual LDL cholesterol was associated with raised risk of myocardial infarction (OR 1·54, 95% CI 1·45-1·63; appendix p 22). In a mendelian randomisation analysis, a 1 SD increase in LDL cholesterol due to genetic score was also associated with risk of myocardial infarction (OR 2·13, 95% CI 1·69-2·69, p=2×10 -¹⁰; table 4). From observational epidemiology, a 1 SD rise in usual HDL cholesterol was associated with lowered risk of myocardial infarction
Observational epidemiology Genetically raised
Odds ratio (95% CI) per 0·03 mmol/L (1 mg/dL) increase in plasma HDL cholesterol p value Odds ratio (95% CI) per 0·03 mmol/L (1 mg/dL) increase in plasma HDL cholesterol p value
Cohort
Atherosclerosis Risk in Communities Study 0·97 (0·96-0·98) 7×10 ¹⁸ 0·96 (0·86-1·07) 0·44
Copenhagen City Heart Study 0·98 (0·98-0·99) 6×10 ¹³ 1·09 (0·95-1·26) 0·21
Malmo Diet and Cancer Study, Cardiovascular Cohort 0·97 (0·96-0·98) 1×10 ⁶ 0·82 (0·66-1·01) 0·06
Framingham Heart Study 0·96 (0·94-0·98) 4×10 ⁶ 1·17 (1·00-1·37) 0·06
Health Professionals Follow-up Study ·· ·· 1·84 (0·39-8·62) 0·16
Danish Diet, Cancer, and Health Study ·· ·· 1·05 (0·79-1·41) 0·71
Meta-analysis of cohort studies
Per 0·03 mmol/L (1 mg/dL) increase in plasma HDL cholesterol 0·98 (0·97-0·98) 4×10 ³⁶ 1·02 (0·95-1·09) 0·64
Per 0·39 mmol/L (15 mg/dL) increase in plasma HDL cholesterol 0·70 (0·66-0·74) 4×10 ³⁶ 1·28 (0·46-3·61) 0·64 
Discussion
For a biomarker directly involved in disease patho genesis, we expect a genetic variant that modulates the biomarker to likewise confer risk of disease. We tested this hypothesis for two plasma biomarkers: LDL and HDL cholesterol. SNPs aff ecting LDL cholesterol were consistently related to risk of myocardial infarction. However, we unexpectedly found that LIPG Asn396Ser, a genetic variant that specifi cally and substantially increases plasma HDL cholesterol, did not reduce risk of myocardial infarction. A genetic score combining 14 variants exclusively related to HDL cholesterol also showed no association with risk of myocardial infarction (panel). These results challenge several established views about plasma HDL cholesterol. First, these data question the concept that raising of plasma HDL cholesterol should uniformly translate into reductions in risk of myocardial infarction. We raise the strong possibility that a specifi c means of raising of HDL cholesterol in human beings-namely, inhibition of endothelial lipase-will not reduce risk of myocardial infarction. In animal models, inhib ition or deletion of the endothelial lipase gene increases HDL cholesterol concentrations, 27 but there has been debate as to the consequent eff ect on atherosclerosis. One report suggested that mice deleted for Lipg on an Apoe knockout genetic background have decreased aortic atherosclerosis, 28 but a subsequent study showed no eff ect of Lipg deletion on aortic atherosclerosis. 29 Second, these fi ndings emphasise the potential limitation of plasma HDL cholesterol as a surrogate measure for risk of myocardial infarction in intervention trials. The data presented here using mendelian randomisation are consistent with results from completed randomised controlled trials focused on raising plasma HDL cholesterol. Hormone replacement therapy raised plasma HDL cholesterol but did not lower risk of myocardial infarction. 30 In the Atherothrombosis Inter vention in Metabolic Syndrome with Low HDL Cholesterol/High Triglyceride and Impact on Global Health Outcomes (AIM-HIGH) trial, 31 the addition of long-acting niacin to background simvastatin increased HDL cholesterol and lowered triglycerides but did not lower risk of cardio vascular events.
Of note, at the cholesterol ester transfer protein (CETP) gene, we did fi nd that common genetic variation reduces risk of myocardial infarction by 4%, a result in line with an earlier meta-analysis. 32 However, the CETP variant both increases HDL cholesterol and lowers LDL cholesterol 17 in a manner similar to pharmacological inhibitors of CETP. 33 As such, whether the protection aff orded by the CETP variant is due to the change in HDL or LDL cholesterol is diffi cult to distinguish.
Third, biomarkers that assay HDL function might overcome some limitations of standard HDL cholesterol assays. However, a challenge will remain-namely, to prove that new functional HDL biomarkers refl ect a causal association with myocardial infarction rather than an indirect one, as seems to be the case with plasma HDL cholesterol. For example, using a new in-vitro measure involving mouse macrophages and human serum, Khera and colleagues 34 showed an inverse correlation between a specifi c functional property of HDL, cholesterol effl ux capacity, and coronary artery disease status. The present study suggests that a fruitful approach to the causal evaluation of such 7, 12, 15 In each of these previous reports, genetically increased plasma HDL cholesterol was not associated with risk of ischaemic heart disease.
Interpretation
The present study tested a naturally occurring loss-offunction variant in the endothelial lipase gene and, with this new instrument, we confi rm that genetically raised plasma HDL cholesterol is not associated with risk of myocardial infarction. The study further extends previous work by testing an instrument consisting of 14 common variants exclusively associated with plasma HDL cholesterol. A genetic score consisting of these 14 variants was not associated with risk of myocardial infarction. These results show that some ways of raising HDL cholesterol might not reduce risk of myocardial infarction in human beings. Therefore, if an intervention such as a drug raises HDL cholesterol, we cannot automatically assume that risk of myocardial infarction will be reduced.
functional measures in human beings might be largescale study of relevant inherited DNA variation of HDL function.
There are inherent limitations to the mendelian randomisation study design. Naturally occurring genetic variation could be a useful instrument to assess causality provided that several requirements have been satisfi ed. 35, 36 First, one needs suitable genetic variants for the study of the modifi able exposure of interest (in our case, plasma HDL cholesterol). Although many loci are associated with plasma HDL cholesterol, we found LIPG Asn396Ser to be particularly informative because it is specifi cally associated with substantial increases in HDL cholesterol. Additionally, we evaluated a set of 14 common genetic variants that also exclusively aff ected HDL cholesterol. Both instruments, LIPG Asn396Ser and the genetic score, produced similar results.
Second, reliable genotype-to-intermediate-phenotype and intermediate-phenotype-to-disease eff ect estimates are needed. To obtain as precise estimates as possible, we derived SNP-to-lipid eff ect estimates from analysis of a large sample involving more than 24 000 participants. Estimates of plasma lipid to myocardial infarction were derived from meta-analysis of four large cohort studies involving more than 25 000 participants.
Third, there must not be pleiotropic eff ects of the genetic variants of interest. We cannot exclude all potential pleiotropic eff ects of the LIPG Asn396Ser SNP; however, we have assessed but did not detect pleiotropic eff ects on other cardiovascular risk factors including LDL cholesterol, small LDL particle concentration, triglycerides, body-mass index, systolic blood pressure, plasma C-reactive protein, and type 2 diabetes status.
Finally, the absence of association of individual SNPs with myocardial infarction could be due to low statistical power. However, for the crucial SNP in the mendelian randomisation study for plasma HDL cholesterol, we had suffi cient power. In this study, LIPG Asn396Ser has been tested in 20 913 myocardial infarction cases and 95 407 myocardial-infarction-free participants. We had 90% power to detect the expected 13% reduction in risk of myocardial infarction for the LIPG Asn396Ser variant (at a two-sided α of 0·05).
In summary, our results showed that polymorphisms related to plasma LDL cholesterol were consistently associated with risk of myocardial infarction, whereas this was not the case for variants related to plasma HDL cholesterol. A polymorphism in the endothelial lipase gene and a genetic score of 14 common SNPs that specifi cally raised HDL cholesterol were not associated with myocardial infarction, suggesting that some genetic mechanisms that raise HDL cholesterol do not lower risk of myocardial infarction. Hence, interventions (lifestyle or pharmacological) that raise plasma HDL cholesterol cannot be assumed ipso facto to lead to a corresponding benefi t with respect to risk of myocardial infarction.
